Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy.
The immunomodulator fingolimod (FTY720) induces lymphopenia by inhibiting lymphocyte egress from thymus and secondary lymphoid organs (SLOs). It is phosphorylated mainly by sphingosine kinase (SK) 2 in vivo. FTY720-phosphate (FTY-P) activated and rapidly internalized S1P(1), which is the major sphingosine 1-phosphate (S1P) receptor for mediating lymphocyte egress. Although FTY-P is thought to be the active metabolite for triggering the onset of lymphopenia, nonphosphorylated FTY720 was much more potent in inhibiting cellular calcium flux and splenocyte chemotaxis via S1P(1) than FTY-P after preincubation. Determination of both compounds by liquid chromatography coupled to mass spectrometry revealed efficient uptake and accumulation of FTY720 but not FTY-P by splenocytes. Coculture experiments of B and T cells with and without FTY720 pretreatment led to rapid cellular transfer and phosphorylation by mouse lymphocytes. The presence of FTY720 in lymphoid tissues of FTY720-treated SK2-deficient mice without onset of lymphopenia excluded a potential role of the nonphosphorylated compound for lymphocyte egress. Local concentrations of both phosphorylated and nonphosphorylated FTY720 were much higher in lymphoid tissues than in blood. Therefore, we conclude that cellular accumulation of FTY720 generates a reservoir in thymus and SLOs, leading to sustained FTY-P production and activation of S1P(1) within tissues.
Sensken
Sven-Christian
SC
Institute for Immunology, Hannover Medical School, 30625 Hanover, Germany.
Bode
Constantin
C
Gräler
Markus H
MH
D000818:Animals; D002118:Calcium / Q000378:metabolism; D002633:Chemotaxis / Q000187:drug effects / Q000502:physiology; D002853:Chromatography, Liquid; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D008113:Liver Neoplasms; D008114:Liver Neoplasms, Experimental; D008221:Lymphoid Tissue / Q000187:drug effects / Q000276:immunology*; D013058:Mass Spectrometry; D010755:Organophosphates / Q000302:isolation & purification / Q000494:pharmacology; D011409:Propylene Glycols / Q000302:isolation & purification / Q000493:pharmacokinetics* / Q000494:pharmacology; D051381:Rats; D049349:Receptors, Lysosphingolipid / Q000187:drug effects / Q000378:metabolism; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000494:pharmacology; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000502:physiology
C525008:FTY 720P; D007166:Immunosuppressive Agents; D010755:Organophosphates; D011409:Propylene Glycols; D049349:Receptors, Lysosphingolipid; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; D002118:Calcium